

NEWSRELEASE

DELMEDICAINVESTMENTS January 22nd 2007



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.

MUCOAD™ UK PATENT GRANTED

Fortune Apex Development ('Fortune Apex') today announced that patent application number GBO521708.8 for MUCOAD™ Mucoadhesive compositions has been officially approved by the UK Patent Office.

MUCOAD™ Mucoadhesive compositions will now be commercially protected from competitors seeking to market substitute Mucoadhesive systems in the United Kingdom. Considered the foremost global Patent Office, the UK announcement will form a precedent for all other applications filed.

The patented MUCOAD™ Mucoadhesive compound can now fully exploit a niche position in an extremely lucrative market. Fortune Apex are now in a position to grant license agreements offering up to 20 years protection.

Fortune Apex continues strategic negotiations with large pharmaceutical manufacturers who seek to improve efficacy and add value to their existing product range with the unique MUCOAD™ compound.

Via their strategic partnership agreement, Delmedica Investments actively supports Fortune Apex in the promotion, licensing and commercialisation of MUCOAD™ technology.

DELMEDICA

Suite 2207-09 • Tower Two Lippo Centre • 89 Queensway • Admiralty • Hong Kong

www.delmedicainvestments.com